Stanexdnc

Heparin is an anticoagulant that prevents the formation of blood clots. With the onset of the COVID-19 pandemic, many drugs have been under review for a potential cure for a remedy for the infection. Depending on the severity of the case, different kinds of drugs are administered to the patient to cure them of the infection. In non-critical patients infected with COVID-19, a therapeutic dose of heparin increased their probability of survival with minimal use of cardiovascular or respiratory organ support in comparison to regular care thromboprophylaxis. Patients admitted with COVID-19 regularly have macrovascular and microvascular thrombosis and inflammation. Heparin has antithrombotic, anti-inflammatory, and possibly antiviral properties. This has led to a hypothesis that if heparin is administered in specific doses, the effect of the infection can be contained to a large extent. Tests have been conducted worldwide to put this theory into practice which has given positive results. However, its effectiveness is nil in the case of patients who are critically ill with COVID-19.

At Stanex, we focus on producing high-quality drugs approved by the WHO, GMP, and USFDA. We offer a wide range of drugs including heparin for several requirements. Our products are manufactured in state-of-the-art plants equipped with the latest technology. Our R&D team works tirelessly to ensure that every product rolled out of our plants meet all the quality parameters while ensuring our manufacturing processes are sound. Our true endorsement comes from our clients who are located in over 50 countries who trust us with their requirements every time. Creating a sustainable ecosystem where all stakeholders can join hands with a common goal is our true objective. Find out more about us, visit our website now.